[
    [
        {
            "time": "",
            "original_text": "腰部位药企IPO也难了，沃森生物终止港股挂牌，但20亿的研发费用缺口怎么办？",
            "features": {
                "keywords": [
                    "药企",
                    "IPO",
                    "沃森生物",
                    "港股",
                    "研发费用",
                    "缺口"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "腰部位药企IPO也难了，沃森生物终止港股挂牌，但20亿的研发费用缺口怎么办？",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]